In this paper we present M4CVD: Mobile Machine Learning Model for Monitoring Cardiovascular Disease, a system designed specifically for mobile devices that facilitates monitoring of cardiovascular disease (CVD). The system uses wearable sensors to collect observable trends of vital signs contextualized with data from clinical databases. Instead of transferring the raw data directly to the health care professionals, the system performs analysis on the local device by feeding the hybrid of collected data to a support vector machine (SVM) to monitor features extracted from clinical databases and wearable sensors to classify a patient as "continued risk" or "no longer at risk" for CVD. As a work in progress we evaluate a proof-of-concept M4CVD using a synthetic clinical database of 200 patients. The results of our experiment show the system was successful in classifying a patient's CVD risk with an accuracy of 90.5%.
Introduction
Cardiovascular Disease (CVD), which includes heart attack, stroke and hypertension, continues to be a leading cause of death in the developed world 1 . While CVD related deaths in the developed world have recently decreased 2 , chronic CVD continues to increase due to an aging population and rising obesity which is intensifying the effects of chronic disease 3 . In 2009, 1.6 million Canadians reported having heart disease 4 . CVD has also become a burden on healthcare systems as the management of CVD is complex and requires continuous monitoring of the patients by health professionals 5 . Remote patient monitoring is increasingly becoming an attractive solution for the management of CVD. Patients and care providers can both benefit from remote monitoring as it helps patients be more engaged in their health through self-reported outcomes and provides support for cost-effective care. Therefore there is a need for a monitoring device for CVD patients that not only communicates collected data between remote patients and care providers but also processes the raw data and summarizes that data in a meaningful way that helps health professionals make more accurate and timely decisions when the patient is outside of the care settings. Such a device should yet be usable and easily accessible by patients. Due to the crucial role of remote monitoring for CVD patients, we have witnessed significant efforts from research communities and industry to propose and design a variety of CVD monitoring devices. A number of devices reviewed in this paper monitor single 6, 7 or multiple 8, 9 physiological signals using wearable sensors. Machine learning algorithms (MLA) have been used to analyze physiological data to monitor CVD 10 or analyze clinical databases to design CVD diagnostic support systems 11 . Our review of the existing proposals on CVD monitoring devices show that they do not automatically leverage the patient's clinical data when analyzing the physiological data. Currently health professionals implicitly use clinical data when examining the results from RPM systems. Furthermore, current systems using MLAs perform analysis on remote servers requiring a constant network connection and cannot be used in poor coverage zones in rural areas or low-income countries. The devices also require complex platforms with peripheral devices as opposed to leveraging built in mobile device capabilities as we propose here. To address the gap in the current devices we propose a system, designed specifically for mobile devices, that facilitates monitoring cardiovascular disease. The system leverages built-in capabilities of mobile devices (e.g., computer processing capabilities, activity tracking via accelerometers, health applications) plus wearable sensors to collect observable trends of vital signs. The system also incorporates data from clinical databases to provide valuable contextual information for data captured through physiological sensors. Instead of transferring the raw data directly to the professionals, the system performs local analysis by feeding the hybrid of collected data to a support vector machine (SVM) to monitor features extracted from clinical databases and wearable sensors. The system then classifies a patient as "continued risk" or "no longer at risk" for CVD. In this paper we build a proof-of-concept for our proposed cardiovascular monitoring system called M4CVD: Mobile Machine-Learning Model for Monitoring Cardiovascular Disease. As a work in progress we evaluate M4CVD using a synthetic clinical database of 200 patients. Our preliminary results show that the system achieved a cross-validated accuracy of 90.5%.
The paper is structured as follows: Section 2 provides an overview of our proposed system and the specifications of the four main components i.e., data collection, data processing, machine learning, and decision making. In Section 3 we report the experimental procedure and the results of the evaluation of M4CVD using synthetic sensor and clinical data. In Section 4 we discuss the potential impact of the interpreted results on clinical decision improvement for the patients outside of the clinical settings. Section 5 describes the related research. We conclude in Section 6.
Proposed System
In this section we present our proposed system as shown in Fig. 1 . Using a SVM the system monitors features extracted from wearable sensors and clinical databases. The system classifies a patient as "continued risk" or "no longer at risk" for CVD. The decision input and output data is transmitted to a server for storage and remote viewing. Five components of the system architecture are Input, Data Processing, Machine Learning, Decision Making and Output. Data Processing, Machine Learning and Decision Making are all performed on the mobile device.
Inputs
Our proposed system obtains input data from two sources: 1) physiological signals measured using wearable sensors and 2) clinical data from health records. The system improves on previous devices which have been limited to one input source. Physiological signals include electrocardiogram (ECG), blood pressure (BP), stress level through galvanic skin response (GSR) and accelerometers as an indicator of physical activity. Wearable sensors are worn by the patient and the signals are collected by an embedded device such as a data acquisition microcontroller or application-specific integrated circuit. The embedded device also preprocesses the data and transmits the sensor data to the mobile device. Other sensors such as accelerometers are built into the mobile device themselves. Wearable sensor data, which are not stored in clinical databases due to their large file size, allows for the examination of observable long-term trends but lacks contextual information.
Our device will use clinical databases to provide context to physiological measurements. Databases will include information such as age, gender, body mass index (BMI) and medication history. Databases also contain records of physiological readings such as ECG, BP and SpO 2 . Clinical data is manually updated by healthcare professionals during a patient's visit. As a result clinical databases are updated less frequently compared to wearable systems and any trends in the clinical data will take longer to be detected. In contrast to wearable sensors, databases contain records on large patient populations which provides a large training set for the SVM. Through the combined input data, our device will be able to rapidly interpret physiological measurements in the context of a patient's medical history to calculate the patient's risk of CVD.
Data Processing
The input data must be processed into a set of features before becoming suitable inputs for a SVM. The processing will be done through noise reduction, feature extraction and data normalization. Raw wearable sensor data contains noise from both the environment and other biological signals that are not currently under observation. Motion artifacts also affect the raw data as the sensors are disturbed during day-to-day use. Noise and motion artifacts corrupt the physiological signal and prevent useful feature extraction. Noise reduction will be completed with low/ high pass filters to improve the signal-to-noise ratio 12 . The second aspect of data processing is feature extraction. While continuous sensor data (e.g., ECG, accelerometers) are used as input features to a SVM, our device will extract additional features from sensor data using signal processing techniques. By using feature extraction we can convert continuous signals to discrete values. For example, from an ECG signal we compute time domain features such as heart rate (HR) and R-R interval. ECG frequency domain features include power spectral density and band power 13 . While discrete features provide better inputs to the SVM there is still a challenge. The numeric ranges change between the features as each reflects different physiological values. During SVM training, features with larger ranges may be assigned more weight over smaller feature ranges regardless of the importance of the feature to classification accuracy 14 . Normalizing the features to a range of (0,1) or assigning feature values to discrete categories (1,2,3,4) eliminates this bias. For example, systolic blood pressure has a wide physiological range between 120-150 mmHg. On the other hand, BMI has a smaller range of 16-50 kg/m 2 . Systolic blood pressure can be normalized by setting a threshold value where the patient's BP is either above (BP= 1) or below (BP=0) the threshold. BMI is represented by categories of low, medium, high and highest risk (1, 2, 3, 4) . The features used for M4CVD will be from both clinical and wearable data sets described by discrete or categorical classifications.
Machine Learning Algorithm
The next step as shown in Fig.1 is the design and training of the machine learning algorithm for the calculation of a decision regarding patient risk. The support vector machine 15 , defined in Eq.1, creates a classification boundary (hypersurface) to separate input vector x i into one of two classes y i {0, 1}. The optimal SVM finds the w and b that minimize the empirical error (risk) and the complexity of the classifier, a trade-off achieved using the structural risk minimization (SRM) principle 16 . In the training stage, the SVM is optimized using a set of input vectors x i with known class labels y i . In the testing stage, new data vectors with unknown classes are then classified.
The Vapnik-Chervonenkis (VC) theory 16 allows us to control the classifier complexity in Eq.2 by minimizing the classifier margin, w , between the class boundary and the dividing hypersurface with bias b. The slack variable ξ and the penalty constant C allows for some feature points to appear on the wrong side of the soft margin of the hypersurface. As C → 0 more points are allowed to fall on the wrong side of the hypersurface which increases generalization at the expense of training accuracy. When two classes are not linearly separable in 2D space a kernel φ, defined in Eq. 3, is used to map x i to a higher dimension features space φ(x i ). A non-linear separating hypersurface
is then constructed in the feature space. A popular kernel for SVMs is the radial basis function (RBF) 17, 18 and is used when the number of training examples (i) is greater than the number of features (x) as is the case with our data. The SVM and the kernel have two parameters that require optimization by the user: the penalty constant C, and the kernel width σ 2 . The parameter selection is a balance between the SVM model's training accuracy and generalization. K-Fold cross validation is a procedure to determine the optimized C and σ 2 by dividing the input data into K folds and training the SVM on each K-1 fold and testing on K th fold. A grid search of each unique combination of C and σ 2 is then conducted and the values that provide the best cross-validated classification accuracy are chosen. A fine grid search focused around the optimized parameter selection from the broad grid search is conducted to further increase accuracy. Once the SVM has been trained it can be applied to classify new data. Interested readers are referred to Müller et al. 19 for a more detailed explanation on SVM theory. The SVM is a popular algorithm for our classification situation due to its ability to map features to higher dimensional data through a kernel function. The SVM was chosen because of its ability to construct a robust classifier from only a small data set. In addition it has good generalization properties allowing it to classify new data. SVMs have been used in RPM systems to detect arrhythmia by comparing a patient's current ECG with their baseline ECG 20 .
Decision Making and Output
The proposed MLA is trained with patients who are "continued risk" (Class 1) and "no longer at risk" (Class 0) for heart disease. Class 1 patients are identified as needing further clinical intervention. Class 0 patients are those that show positive response to treatment and are monitored to detect any relapses. The SVM creates a higher dimensional space where a patient is either within the hypersurface (Class 1) or outside the hypersurface (Class 0) 15 . The SVM has a binary output (0,1) which is interpreted and displayed to the user. The device allows patients to become a more active contributor in their treatment plan as they can observe and monitor the results of the mobile MLA. The input physiological and clinical data and resulting classification decision are transmitted and stored in a remote server which allows health care professionals to review results with or without the patient's presence.
Experimental Procedure and Results
In this section we describe the experimental procedure for the M4CVD proof-of-concept. A synthetic database containing thirteen features is created as described in Section 3.1. In Section 3.2 we describe how the SVM is configured and trained on the synthetic patient records. The SVM results are described in Section 3.3 .
Experimental Setup of Data Collection
A database of 200 synthetic patient records was created using MATLAB. A synthetic database was chosen to allow complete control on feature choice and feature distribution to provide a wide range of training scenarios for the SVM. No signal processing was required on the synthetic features which did not suffer from noise or missing values. The patient record contained features chosen with the help of a medical expert who subsequently diagnosed the synthetic patient records. Each feature included in the database is a risk factor for cardiovascular disease 21 . The thirteen features are shown in the first column of Table 1 . The second and third column of Table 1 shows that the features that have been used in clinical databases 22, 23 as well as wearable sensors. The features represent either continuous (e.g., age, HR) or discrete (e.g., smoking, stress) vital signs. Each feature has a different physiological range and level that corresponds to an increased risk for CVD according to The Canadian Heart and Stroke Foundation 21 . For example, the patient is at a higher risk of CVD if the patient's cholesterol exceeds 5.2 mmol/L. Our database used a binary (0,1) value to represent the patient's cholesterol level in regards to this threshold value in order to be a suitable SVM input type as discussed in Section 2.2. Most of the risk factors except for age, HR and R-R interval are represented by a binary or categorical values in reference to their physiological thresholds. HR and R-R interval remain continuous to simulate the data collected from a wearable ECG sensor.
A single risk factor outside its physiological range is rarely sufficient to determine a patient's overall level of CVD risk. Rather it is the combination of all the patient's risk factors. In order to effectively train the SVM algorithm the synthetic database contained a wide representation of many vital sign combinations. To achieve this, the features were populated using MATLAB's random generator library. The features were evenly distributed within their respective physiological ranges to maximize the number of patient records with different feature combinations. Initially, age and BMI, two major risk factors, were also randomly and evenly distributed over certain physiological ranges. However, this resulted in a low patient population that was no longer at risk for CVD (7%). Age 24 and BMI 25 were then populated based on census data to better represent population distribution. Using the new distributions for age and BMI (Fig.2) the number of "no longer at risk" patients increased to 21.5% which indicates that accurate feature distribution is important when creating the database. Table 1 (last column) shows each feature's distribution within the database. Each possible feature value was uniformly represented in the database which limits the bias towards specific conditions. Such a uniform distribution increases the number of unique feature combinations when examining the patient records. The resulting SVM training set contains a wide variety of patient data. The database contained 157 patients classified as "continued risk" (78.5%), and 43 patients "no longer at risk" (21.5%) which is a fair representation of a real population as CVD is a chronic disease and patient's in this type of database are at an increased risk of CVD. The high proportion of "continued risk" patients indicates that there are far more combination of features that results in a "continued risk" patient compared to a "no longer at risk" patient. 
Experimental Setup of Machine Learning Algorithm
All 200 patient records were used to train the SVM. The RBF kernel has two parameters to configure: 1) the penalty constant C and 2) kernel width σ 2 . A cross-validation was used to train the SVM where the training data is divided into 5 folds (groups). For each (C, σ 2 ) combination, five SVMs were generated using a different group as the testing set and the remaining groups as the training set. The average SVM accuracy was obtained by taking the average accuracy over each unique SVM for a given (C, σ 2 ) pair. The procedure was repeated for a grid search of a combination of C and σ 2 pairs. The pair that provided the best average classification accuracy was chosen. The MATLAB machine learning toolbox was used to implement the SVM. Figure 3 shows the accuracy of the SVM over different (C,σ) combinations. The optimal SVM had an accuracy of 90.5% and training time was 90 seconds. As σ 2 increased the model achieves higher accuracy and increased generalization. However after the peak value, σ=2, the model becomes over fitted and accuracy falls. As C increases the penalty for misclassification goes up. At first, increasing this penalty (allowing less points to fall on the wrong side of the hyperspace) increases accuracy. However over penalizing lowers the generalization of the algorithm. The graph in Fig. 3 can be used to configure the model for optimized accuracy and generalization. Using cross-validation is an analytical approach to determining this optimal point. We can also modify the parameter selection to favor either accuracy or generalization depending on the design requirements.
Results

Discussion
Our first steps towards developing M4CVD was testing a proof-of-concept system which achieved an accuracy of 90.5%. The system was successful in classifying a patient's CVD risk based on data from a synthetic database. Analyzing 200 patients would take a human several hours to complete while the SVM could analyze all the records in less than one hour. The results support the hypothesis that data mining techniques can be used on input data from wearable sensors and clinical databases.
The model also exhibits some limitations. When the medical expert classified the records BMI, smoking, cholesterol and BP emerged as major factors that had a bigger influence on a patient's classification compared to the remaining attributes. If any one of these features were significantly above the acceptable level it increased the patient's chance of being classified as at "continued risk" for CVD. Patients exhibiting multiple major features that were only slightly above the acceptable level had an even higher chance of being classified as at risk. However, patients with minor factors (e.g., stress, exercise) greatly above the acceptable level were still classified "low risk" as long as the major factors were at safe levels. Minor factors were used when classifying borderline patients and so could not be entirely discounted. Table 2 shows a patient record classified as "at continued risk" for CVD due to the presence of just two major features: cholesterol and BP. Patient 30 is a good candidate for cardiovascular treatment by using medication to lower her BP which should result in reclassification to "low risk". We can test the sensitivity of the system by modifying Patient 30's record and retesting the patient's classification level. Patient 30 demonstrates the difficulty in the binary classification as overall CVD risk in medicine is described using multiple risk levels. Patient 30 is not the most severe case in the database while other patients were borderline but were still classified healthy. In these cases the patients lie very close to hypersurface that divides the two classes which could lead to misclassifications. A multiclass SVM model could instead be used to provide health practitioners with a three class monitoring scale of low, medium and high risk. 
Related Work
Multiple devices record ECG for extended periods of time such as CardioNet 6 , a commercial wearable ECG platform, and UUTE 7 , a proposed mobile phone ECG monitor. As these systems only measure a single physiological signal without contextual information they are unable to provide complete information on CVD risk. An improvement on these single monitoring devices are systems such as SmartVest 8 and AMON 9 . Both contain sensors for multiple physiological risk factors (e.g., ECG, BP) inside a t-shirt and wrist device respectively. SmartVest is solely a signal acquisition device. AMON goes beyond data acquisition to assist the physician by displaying only abnormal recordings. While AMON shows limited data interpretation it does not consider the effect of all physiological readings together and does not integrate clinical database information.
The development of monitoring technology has resulted in the recording of large amounts of physiological data increasing the need for effective analysis techniques. Our device will utilize an MLA to analyze the collected data. MLAs have been applied in the medical field for screening, diagnosis, treatment, prognosis, monitoring and disease management 26 . Previous work by Pecchia et al. developed a CVD management program to determine heart failure severity 10 . The system used a classification and regression tree trained on database of physiological data and achieved an accuracy of 96.39% . The system demonstrates the feasibility of using MLAs in a monitoring system. However, the system was not implemented on a mobile device and did not analyze clinical data.
Mobile phones have been shown to have the computational power to support MLAs. Oresko et al. presented HeartToGo, a mobile phone that performed data acquisition, feature extraction and classification of ECG signals 27 . The system used MLAs and achieved an accuracy of 90% in real-time CVD detection but monitored a single wearable sensor. Our device will improve on HeartToGo by measuring multiple sensors and including clinical data.
Current monitoring systems face a number of limitations and focus primarily on data acquisition without conducting local analysis. Our proposed device will improve upon existing CVD monitoring systems by increasing the monitored input data and by using an MLA to perform data analysis on a mobile device. While previous work has proven the effectiveness of the individual components of our device, no work has integrated these characteristics.
Conclusion and Future Work
In this paper, we have demonstrated a new system for the monitoring of cardiovascular disease. The proposed system is based on the SVM which analyzes features extracted from wearable sensors and clinical databases. Such a system will assist health care professionals by presenting relevant and summarized information on a patient's condition from all of the collected data. The proof-of-concept system successfully classified a patient's risk level using synthetic data. In view of these results, we are implementing this system on a mobile device using real data from clinical databases and wearable sensors. The monitoring device will be evaluated by its accuracy in classifying live monitored data. We are investigating methods to test the system's sensitivity to changing patient conditions. Furthermore we will test the system's performance with other MLAs such as neural networks and multi-class SVMs.
